Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Schrödinger

Nasdaq:SDGR
Snowflake Description

Flawless balance sheet with high growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
SDGR
Nasdaq
$2B
Market Cap
  1. Home
  2. US
  3. Healthcare
Company description

Schrödinger, Inc. provides computational platform to accelerate drug discovery and materials design for biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. The last earnings update was 18 days ago. More info.


Add to Portfolio Compare Print
  • Schrödinger has significant price volatility in the past 3 months.
SDGR Share Price and Events
7 Day Returns
-5.7%
NasdaqGS:SDGR
2.4%
US Healthcare Services
-4.1%
US Market
1 Year Returns
-
NasdaqGS:SDGR
16.3%
US Healthcare Services
-14.9%
US Market
SDGR Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Schrödinger (SDGR) -5.7% -11.7% - - - -
US Healthcare Services 2.4% -4.3% -2.4% 16.3% 61.9% 36.3%
US Market -4.1% -19.1% -23.4% -14.9% 3.5% 14.5%
1 Year Return vs Industry and Market
  • No trading data on SDGR.
  • No trading data on SDGR.
Price Volatility
Industry
5yr Volatility vs Market

Value

 Is Schrödinger undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether Schrödinger is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Schrödinger has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Schrödinger. This is due to cash flow or dividend data being unavailable. The share price is $37.95.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Schrödinger's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Schrödinger's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGS:SDGR PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-4.09
NasdaqGS:SDGR Share Price ** NasdaqGS (2020-04-02) in USD $37.95
United States of America Healthcare Services Industry PE Ratio Median Figure of 12 Publicly-Listed Healthcare Services Companies 39.64x
United States of America Market PE Ratio Median Figure of 2,944 Publicly-Listed Companies 12.5x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Schrödinger.

NasdaqGS:SDGR PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:SDGR Share Price ÷ EPS (both in USD)

= 37.95 ÷ -4.09

-9.27x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Schrödinger is loss making, we can't compare its value to the US Healthcare Services industry average.
  • Schrödinger is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Schrödinger's expected growth come at a high price?
Raw Data
NasdaqGS:SDGR PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -9.27x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts
63.1%per year
United States of America Healthcare Services Industry PEG Ratio Median Figure of 11 Publicly-Listed Healthcare Services Companies 3.11x
United States of America Market PEG Ratio Median Figure of 2,008 Publicly-Listed Companies 0.91x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Schrödinger, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Schrödinger's assets?
Raw Data
NasdaqGS:SDGR PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $-15.25
NasdaqGS:SDGR Share Price * NasdaqGS (2020-04-02) in USD $37.95
United States of America Healthcare Services Industry PB Ratio Median Figure of 38 Publicly-Listed Healthcare Services Companies 3.36x
United States of America Market PB Ratio Median Figure of 5,142 Publicly-Listed Companies 1.22x
NasdaqGS:SDGR PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:SDGR Share Price ÷ Book Value per Share (both in USD)

= 37.95 ÷ -15.25

-2.49x

* Primary Listing of Schrödinger.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Schrödinger has negative assets, we can't compare the value of its assets to the US Healthcare Services industry average.

Next steps:

  1. Take a look at Schrödinger's forecasted future earnings and revenues from industry analysts to understand how the company is expected to perform in the future against its competitors and the wider market.
  2. When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Schrödinger's regulatory filings and announcements.
  3. Show me more potentially undervalued companies in the Healthcare Services industry
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Value checks
We assess Schrödinger's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Healthcare Services industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Healthcare Services industry average (and greater than 0)? (1 check)
  5. Schrödinger has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Schrödinger expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
63.1%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Schrödinger expected to grow at an attractive rate?
  • Schrödinger's earnings growth is expected to exceed the low risk savings rate of 1.7%.
Growth vs Market Checks
  • Schrödinger's earnings growth is expected to exceed the United States of America market average.
  • Schrödinger's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGS:SDGR Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGS:SDGR Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts 63.1%
NasdaqGS:SDGR Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 4 Analysts 30.4%
United States of America Healthcare Services Industry Earnings Growth Rate Market Cap Weighted Average 23.8%
United States of America Healthcare Services Industry Revenue Growth Rate Market Cap Weighted Average 14.4%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 12.2%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.1%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGS:SDGR Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGS:SDGR Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 393 133 130 1
2023-12-31 351 117 101 2
2022-12-31 226 13 13 3
2021-12-31 150 17 -18 4
2020-12-31 108 -44 -53 3
2020-04-03
NasdaqGS:SDGR Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 86 -26 -25
2019-09-30 77 -24 -24
2019-06-30 70 -25 -24
2019-03-31 68 -24 -26
2018-12-31 67 -24 -28
2017-12-31 56 -15 -17

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Schrödinger's earnings are expected to grow significantly at over 20% yearly.
  • Schrödinger's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGS:SDGR Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below

All data from Schrödinger Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:SDGR Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 1.90 1.90 1.90 1.00
2023-12-31 1.57 2.24 0.89 2.00
2022-12-31 0.20 0.36 0.03 2.00
2021-12-31 -0.27 -0.08 -0.56 3.00
2020-12-31 -0.89 -0.65 -1.01 3.00
2020-04-03
NasdaqGS:SDGR Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -4.09
2019-09-30 -4.06
2019-06-30 -4.05
2019-03-31 -4.48
2018-12-31 -4.93
2017-12-31 -3.77

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Schrödinger is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess Schrödinger's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Schrödinger has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Schrödinger performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Schrödinger's growth in the last year to its industry (Healthcare Services).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Schrödinger does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Schrödinger's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Schrödinger's 1-year growth to the US Healthcare Services industry average as it is not currently profitable.
Earnings and Revenue History
Schrödinger's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Schrödinger Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:SDGR Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 85.54 -24.57 48.40 39.40
2019-09-30 77.19 -24.18 46.22 37.20
2019-06-30 70.22 -23.96 42.93 35.66
2019-03-31 68.43 -26.19 39.66 35.09
2018-12-31 66.64 -28.43 36.38 34.52
2017-12-31 55.69 -17.39 31.15 27.67

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Schrödinger has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Schrödinger has efficiently used its assets last year compared to the US Healthcare Services industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Schrödinger improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Schrödinger's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Healthcare Services industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Schrödinger has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Schrödinger's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Schrödinger's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Schrödinger is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Schrödinger's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Schrödinger's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Schrödinger has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Schrödinger Company Filings, last reported 3 months ago.

NasdaqGS:SDGR Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 98.26 0.00 85.83
2019-09-30 104.33 0.00 98.30
2019-06-30 115.03 0.00 104.22
2019-03-31
2018-12-31 90.13 0.00 84.07
2017-12-31 36.95 0.00 36.34
  • Schrödinger has no debt.
  • Schrödinger has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Schrödinger has sufficient cash runway for more than 3 years based on current free cash flow.
  • Schrödinger has sufficient cash runway for 2.6 years if free cash flow continues to grow at historical rates of 15.3% each year.
X
Financial health checks
We assess Schrödinger's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Schrödinger has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Schrödinger's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Schrödinger dividends. Estimated to be 0% next year.
If you bought $2,000 of Schrödinger shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Schrödinger's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Schrödinger's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGS:SDGR Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
Global Healthcare Services Industry Average Dividend Yield Market Cap Weighted Average of 29 Stocks 0.7%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1941 Stocks 3.1%
United States of America Minimum Threshold Dividend Yield 10th Percentile 1.1%
United States of America Bottom 25% Dividend Yield 25th Percentile 2%
United States of America Top 25% Dividend Yield 75th Percentile 5.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGS:SDGR Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2020-04-03

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Schrödinger has not reported any payouts.
  • Unable to verify if Schrödinger's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Schrödinger's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Schrödinger has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Schrödinger's dividends in 3 years as they are not expected to pay a notable one for United States of America.
X
Income/ dividend checks
We assess Schrödinger's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Schrödinger afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Schrödinger has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Schrödinger's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Ramy Farid
COMPENSATION $633,101
AGE 54
TENURE AS CEO 3.3 years
CEO Bio

Dr. Ramy Farid, Ph.D. serves as the President of Schrödinger, LLC and has been its Chief Executive Officer since January 2, 2017. Dr. Farid served as Director of Morphic Holding, Inc. from June 2016 until June 10, 2019. Dr. Farid Co-Founded Nimbus Therapeutics, Inc. in 2009 and served as its President. Dr. Farid served as Senior Vice President of Scientific Development and Program Management of Schrödinger, LLC. Dr. Farid joined Schrödinger in 2002. He serves as a Director of Nimbus Therapeutics, Inc., Morphic Rock Therapeutic, Inc. and Schrödinger, LLC. He was an Assistant Professor in the Chemistry Department of Rutgers University. His research at Rutgers focused on computational protein design, design of highly stable variants of native proteins and construction of synthetic hemoproteins, hydrolytic enzymes and protein-based solar energy conversion devices. He was an NIH Postdoctoral Fellow in the Department of Biochemistry and Biophysics at the University of Pennsylvania. Dr. Farid received his PhD in Chemistry from Caltech in 1991.

CEO Compensation
  • Ramy's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Ramy's remuneration is lower than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Schrödinger management team in years:

3.2
Average Tenure
49
Average Age
  • The tenure for the Schrödinger management team is about average.
Management Team

Ramy Farid

TITLE
CEO, President & Director
COMPENSATION
$633K
AGE
54
TENURE
3.3 yrs

Richard Friesner

TITLE
Co-Founder
COMPENSATION
$347K
AGE
66

Yvonne Tran

TITLE
Executive VP
COMPENSATION
$548K
AGE
48
TENURE
10.3 yrs

Cony D'Cruz

TITLE
Executive VP & Chief Business Officer
COMPENSATION
$588K
AGE
56
TENURE
4.3 yrs

Joel Lebowitz

TITLE
CFO & Executive VP
COMPENSATION
$941K
AGE
55
TENURE
1.4 yrs

Pat Lorton

TITLE
Senior VP & CTO
AGE
35
TENURE
3 yrs

Robert Abel

TITLE
Executive Vice President of Science
AGE
36
TENURE
0.3 yrs

Shane Brauner

TITLE
Senior VP & Chief Information Officer
AGE
41
TENURE
3.3 yrs

Shi-Yi Liu

TITLE
Senior Vice President of Marketing

Jennifer Daniel

TITLE
Senior VP & Chief Human Resources Officer
AGE
49
TENURE
3.2 yrs
Board of Directors Tenure

Average tenure and age of the Schrödinger board of directors in years:

1.3
Average Tenure
59
Average Age
  • The average tenure for the Schrödinger board of directors is less than 3 years, this suggests a new board.
Board of Directors

Michael Lynton

TITLE
Independent Chairman of the Board
AGE
59
TENURE
1.5 yrs

Ramy Farid

TITLE
CEO, President & Director
COMPENSATION
$633K
AGE
54

Richard Friesner

TITLE
Co-Founder
COMPENSATION
$347K
AGE
66
TENURE
3.8 yrs

Gary Sender

TITLE
Independent Director
COMPENSATION
$130K
AGE
57
TENURE
0.8 yrs

Tim Wright

TITLE
Independent Director
AGE
63

Rosana Kapeller-Libermann

TITLE
Independent Director
COMPENSATION
$130K
AGE
55
TENURE
1.3 yrs

Nancy Thornberry

TITLE
Independent Director
COMPENSATION
$308K
AGE
62
TENURE
0.6 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
12. Feb 20 Buy Bill & Melinda Gates Foundation Asset Trust Company 10. Feb 20 10. Feb 20 588,235 $17.00 $9,999,995
10. Feb 20 Buy Deerfield Management Company, L.P. Company 10. Feb 20 10. Feb 20 250,000 $17.00 $4,250,000
X
Management checks
We assess Schrödinger's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Schrödinger has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Schrödinger, Inc. provides computational platform to accelerate drug discovery and materials design for biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. The company operates through two segments, Software and Drug Discovery. It segment is focused on selling its software for drug discovery in the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment develops a pipeline of preclinical and clinical drug discovery programs through its computational platform in collaboration with pharmaceutical companies. Schrödinger, Inc. has a strategic collaboration with Twist Bioscience Corporation. The company was founded in 1990 and is based in New York.

Details
Name: Schrödinger, Inc.
SDGR
Exchange: NasdaqGS
Founded: 1990
$2,400,920,487
63,265,362
Website: http://www.schrodinger.com
Address: Schrödinger, Inc.
120 West 45th Street,
17th Floor,
New York,
New York, 10036,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS SDGR Common Stock Nasdaq Global Select US USD 06. Feb 2020
Number of employees
Current staff
Staff numbers
393
Schrödinger employees.
Industry
Health Care Technology
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/03 05:21
End of day share price update: 2020/04/02 00:00
Last estimates confirmation: 2020/03/25
Last earnings filing: 2020/03/16
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.